Interestingly, recent studies have reported an association between upregulation of ADAM10 and ADAM17 and acquired resistance to trastuzumab and lapatinib in patients with HER2-positive breast cancer [46–49, 53]. This evidence concerns the gene ERBB2 and breast cancer.